The FDA refuses to lift a clinical hold on Cel-Sci’s PhIII drug
Penny stock biotech, Cel-Sci, remains in the FDA’s dog house.
Last fall, the biotech reported that the FDA had put their Phase III study for …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.